Drug intelligence / Profile preview

GIM-122

Development stage: Phase 2
Lead developer: Georgiamune
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa (IgG1K) dual-functioning monoclonal antibody developed for the treatment of advanced solid tumors. It acts as an immune checkpoint inhibitor by targeting and blocking the Programmed cell death protein 1 (PD-1), thereby preventing cancer cells from evading immune detection. In addition to inhibiting PD-1, GIM-122 stimulates activated T cells in a novel manner to enhance anti-tumor immunity. The drug is being developed by Georgiamune and is currently in phase 1/2 clinical trials for patients with advanced or metastatic solid malignancies who have failed prior checkpoint inhibitor therapy[1][3][4][6][7].

Other names: monoclonal antibody GIM-122

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on GIM-122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GIM-122.

Explore the full profile